A study for the metabolomic characteristics of Bevacizumab in the treatment of lung cancer

A study of metabolomic profiling of response to Bevacizumab in the treatment of non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCC-14004438

Enrollment

Unknown

Registered

2014-02-26

Start date

2012-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

chemotherapy:primary prevention

targeted therapy:primary prevention

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: IV non-small cell lung cancer;First-line therapy.

Exclusion criteria

Exclusion criteria: 1. brain metastases and meningeoma; 2. organ transplantation; 3. pregnant and lactation women; 4. alergy to the medicine; 5. other instable factors influencing safety and compliance.

Design outcomes

Primary

Measure	Time frame
Small molecules;lipids;	—

Countries

China

Contacts

Public ContactFang Li

PLA General Hospital

lifang@medmail.com+86 13601261747

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026